# Masonic Cancer Center, University of Minnesota: Phase 2 study closed enrollment, 149 enrolled (Mucopolysaccharidosis Disorders, Hurler Syndrome)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Masonic Cancer Center, University of Minnesota |
| Sponsor type | Academic and hospital |
| Study | MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis |
| NCT ID | NCT02171104 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Mucopolysaccharidosis Disorders; Hurler Syndrome; Hunter Syndrome; Maroteaux Lamy Syndrome; Sly Syndrome; Alpha-Mannosidosis |
| Intervention types | biological, drug |
| Target enrollment | 149 |
| Site countries | United States |
| Posted | 2014-06-23 |
| Planned start | 2014-07-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 149 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT02171104). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.